Table 2.
Baseline characteristics (M0 day 0 measurements) of the participants by vaccine group.
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | ||
|---|---|---|---|---|---|---|---|---|
| Group* | B-SSF | EE-SSF | E-SSS | E-SSS+D | E-SSF | E-SSF+D | E-SF+D | Total |
| n | 20 | 20 | 30 | 30 | 30 | 30 | 30 | 190 |
| Gender male n (%) | 8 (40) | 9 (45) | 14 (46) | 13 (43) | 13 (43) | 14 (46) | 14 (46) | 87 (45) |
| Age (years) median (IQR) | 33.2 (24.8, 41.3) | 30.9 (24.5, 41.9) | 34.1 (28.7, 39.9) | 36.3 (30.7, 42.0) | 37.1 (32.1, 42.8) | 32.4 (29, 39.5) | 29.2 (26.8, 34.5) | 33.8 (27.3, 40.0) |
| Weight (kg) median (IQR) | 57.2 (46.2, 68.5) | 60.9 (54.5, 69.0) | 61.7 (52.5, 70.5) | 61.0 (54.5, 70.3) | 60.0 (53.2, 73.5) | 64.2 (58.1, 75.6) | 59.5 (54.0, 72.3) | 61.2 (53.2, 71.2) |
| Number with fever n | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hb mean (sd) | 13.4 (12.8, 14.5) | 13.4 (13.3, 14.6) | 13.4 (12.7, 14.8) | 14 (12.4, 14.5) | 13.6 (12.2, 14.5) | 13.3 (12.5, 14.7) | 13.1 (12.5, 13.4) | 13.4(12.5, 14.5) |
| WBC median (IQR) | 7.1 (5.9, 7.5) | 7.0 (6.3, 9.1) | 7.0 (6.4, 8.7) | 6.6 (6.0, 7.7) | 7.0 (5.6, 7.4) | 7.0 (6.3, 8.2) | 6.8 (6.0, 8.0) | 6.9 (6.1, 8.0) |
| Platelets median (IQR) | 312 (273, 345) | 297 (263, 329) | 268 (243, 322) | 260 (226, 309) | 284 (233, 354) | 285 (250, 323) | 267 (224, 309) | 280 (243, 323) |
| Creatinine median (IQR) | 0.7 (0.7, 0.9) | 0.9 (0.7, 1.0) | 0.8 (0.7, 1.0) | 0.9 (0.7, 1.0) | 0.8 (0.7, 1.0) | 0.8 (0.7, 1.0) | 0.8 (0.7, 1.0) | 0.8 (0.7, 1.0) |
| AST median (IQR) | 17 (16, 18) | 18 (14.5, 20) | 18 (16, 20) | 23 (19, 28) | 19 (17, 21) | 20 (18, 26) | 21 (19, 28) | 19 (17, 23) |
| ALT median (IQR) | 14 (12, 17) | 14.5 (11, 20) | 14.5 (11, 20) | 18 (13, 26) | 14 (10, 18) | 16 (13, 24) | 20 (16, 34) | 16 (12, 21) |
| Temperature mean (sd) | 36.1 (0.3) | 36.2 (0.5) | 36.1 (0.3) | 36.1 (0.5) | 36.0 (0.4) | 36.0 (0.6) | 36.1 (0.5) | 36.1 (0.4) |
* B: RTS,S/AS01B; E: RTS,S/AS01E; EE: double dose of RTS,S/AS01E; S: standard dose; F: fractional dose; +D: DHA-PIP+PQ